MYGN vs CDNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 23, 2026

MYGN

50.4
AI Score
VS
CDNA Wins

CDNA

54.2
AI Score

Investment Advisor Scores

MYGN

50score
Recommendation
HOLD

CDNA

54score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MYGN CDNA Winner
Revenue 200.40M 117.70M MYGN
Net Income -34.10M 2.81M CDNA
Net Margin -17.0% 2.4% CDNA
Operating Income -30.70M 1.20M CDNA
ROE -10.1% 0.9% CDNA
ROA -5.1% 0.7% CDNA
Total Assets 673.70M 411.06M MYGN
Cash 124.40M 77.92M MYGN
Current Ratio 2.40 3.40 CDNA

Relative Price Performance (Last 90 Days)

MYGN 1M: -49.6% · 3M: -37.1% CDNA 1M: +63.9% · 3M: +122.6%

Current Technical Phase

MYGN

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 24

RSI (14): 24.4 · Price: $3.02

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (24.8% over 20 days), RSI 81

RSI (14): 81.5 · Price: $47.85

Fundamentals Snapshot

Metric MYGN CDNA
Market Cap
Forward P/E -45.3 37.2
Trailing P/E 21.0
Revenue (TTM)
Revenue Growth -0.2% 0.5%
Gross Margin 0.7% 0.7%
Operating Margin -0.2% 0.0%
EPS -1.18 2.08
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, CDNA is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.